Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Global Commercial Ops. | May 03, 2018 | May 07, 2018 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | SVP ComOps Pres USJap Int | May 13, 2011 | May 17, 2011 |
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | June 11, 2026 | June 15, 2026 |
| MANNKIND CORPMNKD · Entity 4792 | Director | May 20, 2026 | May 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2018 · Filed May 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,147 |
Reported balance
After 2018-05-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-03 · Tax withholding · Disposed 883 · Balance 215,147 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 3,428 RSUs which vest in installments of 1,688 on 5/3/2019 and 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 3,428 RSUs which vest in installments of 1,688 on 5/3/2019 and 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
BRISTOL MYERS SQUIBB CO
Report date May 13, 2011 · Filed May 17, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 203,170 |
Ending reported balance
After 2011-05-13 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2011-05-13 · Exercise / conversion · Acquired 381,750 · Balance 544,178 Row 2 · 2011-05-13 · Sale · Disposed 13,372 · Balance 530,806 F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2011-05-13 · Tax withholding · Disposed 47,869 · Balance 482,937 F2: Shares withheld for payment of taxes and fees upon exercise of stock options. F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2011-05-13 · Tax withholding · Disposed 279,767 · Balance 203,170 F3: Shares withheld for payment of exercise price upon exercise of stock options. F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.51 · Expires 2019-03-02 | Direct | 158,634 |
Reported balance
After 2011-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2011-05-13 · Exercise / conversion · Disposed 110,000 · Balance 158,634 F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2018-03-03 | Direct | 46,495 |
Reported balance
After 2011-05-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2011-05-13 · Exercise / conversion · Disposed 125,000 · Balance 46,495 F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.73 · Expires 2016-03-06 | Direct | 0 |
Reported balance
After 2011-05-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2011-05-13 · Exercise / conversion · Disposed 78,750 · Balance 0 F6: Currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.14 · Expires 2013-03-03 | Direct | 0 |
Reported balance
After 2011-05-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2011-05-13 · Exercise / conversion · Disposed 68,000 · Balance 0 F6: Currently exercisable. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,573.97 |
Reported balance
Holding disclosure · report date 2011-05-13 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,573.97 F4: Based on a plan statement as of the end of the most recent fiscal quarter. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Spouse | 3,675 |
Reported balance
Holding disclosure · report date 2011-05-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,675 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Shares withheld for payment of taxes and fees upon exercise of stock options.
F3: Shares withheld for payment of exercise price upon exercise of stock options.
F4: Based on a plan statement as of the end of the most recent fiscal quarter.
F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date.
F6: Currently exercisable.
BeOne Medicines Ltd.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 83,720 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 18,980 · Balance 83,720 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.
MANNKIND CORP
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 82,781 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 82,781 · Balance 82,781 F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,556 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 16,556 · Balance 16,556 F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
F3: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 5,107 | $22.73 | $116,082.11 |
DisclosureSEC source: 0000014272-06-000099 · hoo523.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,458 F2 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 18,900 | $22.73 | $429,597.00 |
DisclosureSEC source: 0000014272-06-000099 · hoo523.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,351 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| September 20, 2005 Filed Sep 21, 2005 19:31 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000162 · hoo435.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,451 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| July 11, 2005 Filed Jul 12, 2005 19:47 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 639 | $24.82 | $15,859.98 |
DisclosureSEC source: 0000014272-05-000151 · hoo429.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,451 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| June 20, 2005 Filed Jun 22, 2005 16:56 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000129 · hoo413.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,090 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:33 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 55,833 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0000014272-05-000071 · hoo364.xml · derivative · entry 4 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,833 Underlying: Common Stock, $0.10 par value · 55,833 shares Expires 2015-02-28 F3 · derivative.exercise_date: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:33 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 9,306 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000071 · hoo364.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,520 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| July 09, 2004 Filed Jul 12, 2004 21:47 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 587 | $24.19 | $14,199.53 |
DisclosureSEC source: 0000014272-04-000151 · hoo289.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,214 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 63,333 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-04-000072 · hoo224.xml · derivative · entry 4 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,333 Underlying: Common Stock, $0.10 par value · 63,333 shares Expires 2014-03-01 F3 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 10,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000072 · hoo224.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · President US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,801 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.